Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Meropol

Showing results (21-30 of 69) with videos related to

Pageof 7
Sort By:
Cancer Investigation|September 22, 2000
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectantN J Meropol, Y M Rustum, P J Creaven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2001
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panelM L Rothenberg, N J Meropol, E A Poplin, et al.
Hybridoma|August 1, 1991
A neutralizing monoclonal antibody binds to an epitope near the amino terminus of murine granulocyte-macrophage colony-stimulating factorN J Meropol, B L Kreider, V M Lee, et al.
Journal of the National Cancer Institute|January 4, 1995
Seizures associated with leucovorin administration in cancer patientsN J Meropol, P J Creaven, N J Petrelli, et al.
Cryobiology|December 1, 1996
A pilot study of cryochemotherapy for hepatic metastases from colorectal cancerM A Rodríguez-Bigas, D Klippenstein, N J Meropol, et al.
Oncology Nursing Forum|August 24, 2001
Nurses' attitudes toward clinical trials at a comprehensive cancer centerC B Burnett, B Koczwara, L Pixley, et al.
Journal of the American College of Surgeons|October 1, 1996
The management of infectious and noninfectious anorectal complications in patients with leukemiaJ H North, T K Weber, M A Rodriguez-Bigas, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 1998
Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsingN J Meropol, G M Barresi, T A Fehniger, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 10, 1998
Treatment choices by seriously ill patients: the Health Stock Risk Adjustment modelD J Gaskin, J Kong, N J Meropol, et al.
American Journal of Clinical Oncology|December 1, 1996
Phase II study of ZD1694 in patients with advanced gastric cancerN J Meropol, R Pazdur, M Vincent, et al.
Pageof 7

Showing results (21-30 of 69) with videos related to

Sort By:
Pageof 7
Cancer Investigation|September 22, 2000
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectantN J Meropol, Y M Rustum, P J Creaven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2001
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panelM L Rothenberg, N J Meropol, E A Poplin, et al.
Hybridoma|August 1, 1991
A neutralizing monoclonal antibody binds to an epitope near the amino terminus of murine granulocyte-macrophage colony-stimulating factorN J Meropol, B L Kreider, V M Lee, et al.
Journal of the National Cancer Institute|January 4, 1995
Seizures associated with leucovorin administration in cancer patientsN J Meropol, P J Creaven, N J Petrelli, et al.
Cryobiology|December 1, 1996
A pilot study of cryochemotherapy for hepatic metastases from colorectal cancerM A Rodríguez-Bigas, D Klippenstein, N J Meropol, et al.
Oncology Nursing Forum|August 24, 2001
Nurses' attitudes toward clinical trials at a comprehensive cancer centerC B Burnett, B Koczwara, L Pixley, et al.
Journal of the American College of Surgeons|October 1, 1996
The management of infectious and noninfectious anorectal complications in patients with leukemiaJ H North, T K Weber, M A Rodriguez-Bigas, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 1998
Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsingN J Meropol, G M Barresi, T A Fehniger, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 10, 1998
Treatment choices by seriously ill patients: the Health Stock Risk Adjustment modelD J Gaskin, J Kong, N J Meropol, et al.
American Journal of Clinical Oncology|December 1, 1996
Phase II study of ZD1694 in patients with advanced gastric cancerN J Meropol, R Pazdur, M Vincent, et al.
Pageof 7